Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in heart failure with preserved ejection fraction
IRCT20190122042450N2Phase 3Completed
- Sponsor
- Dr. Abidi Pharmaceuticals
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change in E/E' ratio. Started Jun 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on IRCT20190122042450N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190122042450N2.